De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial.
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Background In patients with severe sepsis, no randomized clinical trial has tested the concept of de-escalation of empirical antimicrobial therapy. This study aimed to compare the de-escalation strategy with the continuation of an appropriate empirical treatment in those patients. Methods This was a multicenter non-blinded randomized noninferiority trial of patients with severe sepsis who were randomly assigned to de-escalation or continuation of empirical antimicrobial treatment. Recruitment began in February 2012 and ended in April 2013 in nine intensive care units (ICUs) in France. Patients with severe sepsis were assigned to de-escalation (n = 59) or continuation of empirical antimicrobial treatment (n = 57). The primary outcome was to measure the duration of ICU stay. We defined a noninferiority margin of 2 days. If the lower boundary of the 95 % confidence interval (CI) for the difference in patients assigned to the de-escalation group was less than 2 days, as compared with that of patients assigned to the continuation group, de-escalation was considered to be noninferior to the continuation strategy. Secondary outcomes included mortality at 90 days, occurrence of organ failure, number of superinfections, and number of days with antibiotics during the ICU stay. Results The median duration of ICU stay was 9 [interquartile range (IQR) 5-22] days in the de-escalation group and 8 [IQR 4-15] days in the continuation group, respectively (P = 0.71). The mean difference was 3.4…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We identified direct evidence from 13 studies (1968 patients) [277], including 1 RCT [278]. In our meta-analysis, we observed improved short-term mortality in patients who were de-escalated (RR 0.72; 95% CI 0.57–0.91) (Supplementary Appendix 2).”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [278]
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
The Surviving Sepsis Campaign Guidelines Committee including The Pediatric Subgroup*, Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,290
(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Dellit, T. H., Owens, R. C., McGowan, J. E., Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510393 · Cited by 3,362
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428
Hooton, T. M., Bradley, S. F., Cardenas, D. D., Colgan, R., Geerlings, S. E., Rice, J. C., Saint, S., Schaeffer, A. J., Tambayh, P. A., Tenke, P., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/650482 · Cited by 2,099 · cited 10×
“The choice of antibiotics was based on international guidelines [3, 15–18].”
BackgroundMethodInfluentialIbrahim, E. H., Sherman, G., Ward, S., Fraser, V. J., & Kollef, M. H. (2000) · Chest · doi:10.1378/chest.118.1.146 · Cited by 1,779 · cited 9×
“The durations of ICU stay were 14 [9–31] days and 15 [8–21] days in the de-escalation group and the continuation group, respectively (P = 0.”
BackgroundInfluentialPractice Guidelines for the Diagnosis and Management of Skin and Soft-Tissue Infections
Stevens, D. L., Bisno, A. L., Chambers, H. F., Everett, E. D., Dellinger, P., Goldstein, E. J. C., Gorbach, S. L., Hirschmann, J. V., Kaplan, E. L., Montoya, J. G., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/497143 · Cited by 1,602 · cited 10×
“The choice of antibiotics was based on international guidelines [3, 15–18].”
BackgroundMethodInfluentialSolomkin, J. S., Mazuski, J. E., Bradley, J. S., Rodvold, K. A., Goldstein, E. J. C., Baron, E. J., O'Neill, P. J., Chow, A. W., Dellinger, E. P., Eachempati, S. R., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649554 · Cited by 1,558
Cited by
Items 201–241 of 241
Neumopatías nosocomiales adquiridas durante la ventilación mecánica
Guerin, R., & Constantin, J.-M. (2016) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(15)76025-1 · Cited by 1
Self-citationQuelle définition et quelle stratification de la désescalade antibiotique ?
Zahar, J., Weiss, E., & Tabah, A. (2016) · Réanimation · doi:10.1007/s13546-015-1165-4 · Cited by 1
“Dans ce travail multicentrique effectué en France, la désescalade était définie comme la réduction du spectre de l’antibiotique pivot et l’arrêt au troisième jour de l’antibiotique compagnon ou des molécules initiées pour la couverture d’une éventuelle infection à bactéries multirésistantes et secondairement inutiles…”
Impact of de-escalation on ICU patients'
Waele, J. J. D., Bassetti, M., & Martín‐Loeches, I. (2014)
Pneumopathies nosocomiales acquises sous ventilation mécanique
Guérin, R., & Constantin, J.-M. (2015) · Time to knit · doi:10.1016/s0246-0289(15)65666-3
Self-citationYoshitaka, H. A. R. A., & Nishida, O. (2017) · THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA · doi:10.2199/jjsca.37.811
Rodrigues, C. (2018) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2018.tde-27092018-095050
HOSPITALINĖ GRAMNEIGIAMŲ LAZDELIŲ BAKTERIEMIJA INTENSYVIOSIOS TERAPIJOS SKYRIUJE: KĄ TURIME ŽINOTI?
Adukauskienė, D., Jurevičius, M., Micpovilytė, V., Valančienė, D., & Dambrauskienė, A. (2020) · Health Sciences · doi:10.35988/sm-hs.2020.076
“Keleto perspektyviųjų studijų (2014) rezultatai parodė, kad antibiotikų terapijos siaurinimas nepadidino kritinių būklių pacientų mirštamumo [45-47].”
Improving community-acquired pneumonia treatment by antimicrobial stewardship
Schweitzer, V. A. (2020) · Utrecht University Repository (Utrecht University) · doi:10.33540/406
De-escalation of antibiotic therapy as a part of care strategy about critically ill patients
Adámková, V. (2019) · Anesteziologie a intenzivní medicína · doi:10.36290/aim.2019.047
Waisbren, S. (2021) · Federal Practitioner · doi:10.12788/fp.0101
Carrié, C., Bardonneau, G., Petit, L., Ouattara, A., Gruson, D., Pereira, B., & Biais, M. (2019) · Research Square · doi:10.21203/rs.2.12028/v1
“In a multicenter non-blinded randomized non-inferiority trial, a strategy based on de-escalation of antibiotics resulted in prolonged duration of ICU stay and increased number of superinfections as compared to the continuation of the empirical antimicrobial treatment [21].”
BackgroundAntibioticoterapia probabilista en reanimación
Malaquin, S., Mahjoub, Y., Montravers, P., & Dupont, H. (2017) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(17)85631-0
Calandra, T., & Guery, B. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-73506-1_12
Aldardeer, N. F., Shukairi, A. A., Nasser, M. E., Musawa, M. A., Kalkatawi, B. S., Alsahli, R. M., Ramdan, A. M. E., Qushmaq, I. A., & Aldhaeefi, M. (2023) · Dr Sulaiman Al Habib Medical Journal · doi:10.1007/s44229-023-00027-0
“The mortality rate was similar between groups [22].”
BackgroundResultInfluentialThe Rationale Use of Antimicrobials in Septic Surgical Patients
Domenico, S. L. D., Aseni, P., Clerici, E., & Orcese, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-17273-1_52
Empirical Antibiotic Therapy: De-escalation Demystified
Chacko, J., Pawar, S., Seppelt, I., & Brar, G. (2023) · Springer eBooks · doi:10.1007/978-981-19-9940-6_42
Campos, A. F. (2022) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2022.tde-17042023-110531
Avaliação de tecnologia educacional sobre febre maculosa: ensaio clínico randomizado
Bragagnollo, G. R. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.22.2023.tde-12072023-151052
Otimização do uso de antibióticos na unidade de terapia intensiva: como fazemos
Moniz, P., Fustiga, J., Herculano, M. M., & Póvoa, P. M. S. R. (2024) · Critical Care Science · doi:10.62675/2965-2774.20240017-pt
Young-Sharma, T. E. M. W., Wati, S., Sharma, V., Naidu, R. N., Tong, D., & Jenney, A. (2025) · Antibiotics · doi:10.3390/antibiotics14020124
Antibiothérapie probabiliste en réanimation
Soulier-Zaninka, Q., Bouhlal, M., Alloir, C., Viart, C., Malaquin, S., & Dupont, H. (2025) · EMC-Anesthésie réanimation/Encyclopédie médico-chirurgicale. Anesthésie, réanimation · doi:10.1016/s0246-0289(24)47125-9
Terapia antibiotica probabilistica in rianimazione
Soulier-Zaninka, Q., Bouhlal, M., Alloir, C., Viart, C., Malaquin, S., & Dupont, H. (2025) · EMC - Anestesia-Rianimazione · doi:10.1016/s1283-0771(25)50690-4
Drummond, H., Roarty, C., Groves, H. E., Waterfield, T., & Mills, C. (2026) · BMC Research Notes · doi:10.1101/2025.10.17.25338235
Antibioticoterapia probabilista en reanimación
Soulier-Zaninka, Q., Bouhlal, M., Alloir, C., Viart, C., Malaquin, S., & Dupont, H. (2025) · EMC - Anestesia-Reanimación · doi:10.1016/s1280-4703(25)50766-1
Foucrier, A., Dessalle, T., Tuffet, S., Federici, L., Dahyot‐Fizelier, C., Barbier, F., Pottecher, J., Monsel, A., Hissem, T., Lefrant, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23265236
Self-citationPichon, M., Cremniter, J., & Burucoa, C. (2024) · Figshare · doi:10.6084/m9.figshare.26600497
Pichon, M., Cremniter, J., & Burucoa, C. (2024) · Figshare · doi:10.6084/m9.figshare.26600494
Yoshida, H., Motohashi, T., Bus, L. D., De Waele, J., Takaba, A., Kuriyama, A., Kobayashi, A., Tanaka, C., Hashi, H., Hashimoto, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21251621
Foucrier, A., Dessalle, T., Tuffet, S., Federici, L., Dahyot‐Fizelier, C., Barbier, F., Pottecher, J., Monsel, A., Hissem, T., Lefrant, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23265239
Self-citationZhao, K., Zhang, Z.-D., liang, Y., Wang, Y., & Cai, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26608494
Foucrier, A., Dessalle, T., Tuffet, S., Federici, L., Dahyot‐Fizelier, C., Barbier, F., Pottecher, J., Monsel, A., Hissem, T., Lefrant, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.23265242
Self-citationSieswerda, E., Bax, H. I., Hoogerwerf, J. J., de Boer, M. G. J., Boermeester, M. A., Bonten, M. J. M., Dekker, D., van Wijk, R. G., Juffermans, N. P., Kuindersma, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20479548
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025
Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., et al. (2025) · RWTH Publications (RWTH Aachen) · doi:10.5167/uzh-280465
Buensalido, J. A. L., Malundo, A. F. G., Aherrera, J. A. M., Magno, J. D. A., Maramara, M. K. P., Punzalan, F. E. R., Tolosa, M. T. S., Briones, G., Hernandez, A. M. R., Pantaleon, A. F., et al. (2022) · Philippine Journal of Internal Medicine · doi:10.65564/pjim.10a45be121
Sawada, K., Inose, R., & Muraki, Y. (2026) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-026-00558-2
“The significant cost reductions for broad-spectrum agents (e.g., antipseu-domonal injectables) without corresponding change in overall treatment duration are characteristic of de-escala-tion—a cornerstone of advanced antimicrobial steward-ship [36].”
Koutake, Y., Oishi, H., Nagasaki, Y., Yamada, M., Fujimoto, A., Soejima, K., Nishi, H., Adaniya, G., & Hayashi, T. (2026) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2026.102957
Exploration de la réponse de l'hôte au travers de différentes approches globales
Daumas, A. (2019) · theses.fr (ABES) · doi:10.70675/c844f815z3aa0z4983z9077z1aaa7156ac85
Niinuma, Y., Ishiguro, N., MORIKAKU, Y., Hanaoka, K., Kagami, K., Sugawara, M., & Takekuma, Y. (2026) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2026.10420
“Moreover, evidence from randomized controlled trials indicates that de-escalation based solely on culture results does not influence mortality, 20,21 suggesting that the impact of responsiveness on study outcomes is likely limited.”
Ohnuma, T., Fuller, M., Balamurugan, P., Moehring, R. W., Krishnamoorthy, V., Raghunathan, K., & Treggiari, M. M. (2026) · Journal of Critical Care · doi:10.1016/j.jcrc.2026.155646
Zhang, L., & Ye, H. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-14080-1
“…criterion had greater early illness severity than the eligible cohort did, with higher APACHE II scores (21.6 ± 5.8 vs. 17.9 ± 4.9), higher SOFA scores (10 [8, 13] vs. 8 [6, 10]), more frequent septic shock at diagnosis (56.4% vs. 42.0%), and a higher incidence of MDRO infection (34.6% vs. 22.5%).”
InfluentialSava, M., Codru, I. R., Bereanu, A. S., Fratila, A. M., & Vintilă, B. I. (2026) · Antibiotics · doi:10.3390/antibiotics15090912
“The pre-2016 randomized trial by Leone et al., summarized in several of the included reviews, reported longer total antibiotic treatment and a higher incidence of superinfection following de-escalation, with no significant difference in mortality [67].”
Influential
Metadata
- Authors
- Leone, M., Bechis, C., Baumstarck, K., Lefrant, J.-Y., Albanèse, J., Jaber, S., Lepape, A., Constantin, J.-M., Papazian, L., Bruder, N., Allaouchiche, B., Bézulier, K., Antonini, F., Textoris, J., Martin, C., & For the AZUREA Network Investigators
- Affiliations
- Hôpital Nord (FR)
- Aix-Marseille Université (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Hôpital de la Conception (FR)
- Inserm (FR)
- Hospices Civils de Lyon (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Centre National de la Recherche Scientifique (FR)
- Hôpital de la Timone (FR)
- ORCID
- Venue
- Intensive Care Medicine
- Published
- 2014-08-05
- Volume
- 40
- Issue
- 10
- Pages
- 1399-1408
- ISSN
- 0342-4642 (ISSN-L)
- 1432-1238
- OpenAlex
- W2053430308
- Cited by
- 243
- References
- 32
- Citations by year
- 2026: 10 · 2025: 16 · 2024: 18 · 2023: 18 · 2022: 17 · 2021: 18 · 2020: 28 · 2019: 27 · 2018: 18 · 2017: 22 · 2016: 32 · 2015: 14 · 2014: 5
- FWCI
- 18.32
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-07)
- Open access
- green
- hal.umontpellier.fr
- Licence
- other-oa
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Intensive Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Keywords
- severe sepsis, antibiotic de-escalation, empirical antimicrobial therapy, ICU length of stay, superinfection, antibiotic duration, mortality, organ failure
- MeSH terms
- Aged, Anti-Bacterial Agents, Female, France, Humans, Intensive Care Units, Length of Stay, Male, Microbial Sensitivity Tests, Middle Aged, Multivariate Analysis, Linear Models, Proportional Hazards Models, Sepsis, Withholding Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.